Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims match the supplied FDA label text (e.g., Schedule IV and several listed adverse reactions such as dizziness, insomnia, and dry mouth). However, multiple claims are not supported by the provided label excerpts (e.g., FDA warnings about counterfeit sales online, FDA approval of several versions, OTC availability, specific patient obtainability/price statements, and alternative weight-loss agents). Several safety/label elements mentioned in claims are not present in the supplied label text.
Category Scores
Accurate Statements
Short-term (a few weeks) adjunct in a weight reduction regimen for exogenous obesity in patients with BMI ≥30 kg/m^2, or BMI ≥27 kg/m^2 with other risk factors.
Label section 1 INDICATIONS AND USAGE: short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction for management of exogenous obesity; initial BMI ≥30 kg/m^2 or ≥27 kg/m^2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).
Phentermine is a Schedule IV controlled substance in the United States.
Label section 9.1 Controlled Substance: “Phentermine is a Schedule IV controlled substance.”
Phentermine can cause side effects including dry mouth.
Label section 6 ADVERSE REACTIONS (Gastrointestinal): “Dryness of the mouth …”
Phentermine can cause side effects including dizziness.
Label section 6 ADVERSE REACTIONS (Central Nervous System): “... dizziness, insomnia, ...”
Phentermine can cause side effects including insomnia.
Label section 6 ADVERSE REACTIONS (Central Nervous System): “... insomnia, ...”
Patients taking phentermine should report concerns to their healthcare provider.
Label section 17 PATIENT COUNSELING INFORMATION: patients must be informed about risks and “about the symptoms of potential adverse reactions and when to contact a physician and/or take other action.”
To obtain phentermine, patients must first consult their doctor, who evaluates their medical history and determines if the medication is suitable for them.
Supported only indirectly by the label’s patient counseling about taking instructions and risks requiring physician contact; the provided label excerpts do not explicitly state “consult their doctor and evaluates medical history to determine suitability.”
Unsupported Statements
Phentermine is a prescription medication used for weight loss in obese patients.
The label excerpt provided describes indications but does not explicitly use the term “prescription medication.” The supplied evidence supports the indication (weight reduction in exogenous obesity for specified BMI/risk factors) but not the “prescription medication” phrasing.
Phentermine is only available through a prescription from a licensed healthcare professional.
No excerpt provided states prescription-only availability.
Phentermine cannot be purchased over-the-counter (OTC) from pharmacies or online retailers.
No excerpt provided addresses OTC vs prescription purchasing.
Phentermine products sold online without a prescription are often counterfeit or unauthorized.
No excerpt provided describes counterfeit/unauthorized products being common or tied to online sales without a prescription.
Counterfeit or unauthorized phentermine products sold online pose risks to consumers.
No excerpt provided discusses counterfeit/unauthorized products or associated consumer risks.
The FDA has approved several versions of phentermine.
No excerpt provided discusses FDA approval of multiple versions.
The FDA has issued warnings about counterfeit versions of phentermine sold online.
No excerpt provided contains such warnings.
Phentermine is regulated by the FDA in the United States.
No excerpt provided states FDA regulation of phentermine.
Patients who have a valid prescription can usually obtain phentermine at a reasonable price through a licensed pharmacy.
No excerpt provided addresses availability timing, pricing, or “reasonable price.”
The cost of phentermine can vary depending on the location and pharmacy.
No excerpt provided contains any cost/pharmacy pricing statements.
Orlistat (Alli, Xenical) is an alternative weight loss medication.
The provided label excerpts do not list or discuss orlistat as an alternative.
Liraglutide (Saxenda) is an alternative weight loss medication.
The provided label excerpts do not list or discuss liraglutide as an alternative.
Naltrexone-bupropion (Contrave) is an alternative weight loss medication.
The provided label excerpts do not list or discuss naltrexone-bupropion as an alternative.
To obtain phentermine, patients must first consult their doctor, who evaluates their medical history and determines if the medication is suitable for them.
The excerpts do not explicitly require medical history evaluation to determine suitability; they mainly provide counseling about short-term use and contacting a physician for symptoms.
If prescribed, phentermine can be purchased from a licensed pharmacy with a valid prescription.
No excerpt provided addresses pharmacy purchasing process.
Contradictions
Important Omissions
Dosage and administration details (e.g., specific dose, titration, maximum duration) were not evaluated because no corresponding label text was provided in the excerpts.
Importance:
Moderate
Contraindications and specific warnings/precautions (other than controlled substance and adverse reactions) were not assessed because relevant label sections were not included in the prompt excerpt.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims relate to obtaining phentermine, OTC vs prescription status, and counterfeit/unauthorized products sold online; these are unsupported by the provided label excerpts. Unsupported access/market claims could mislead consumers. Supported adverse reaction claims (dry mouth, dizziness, insomnia) are consistent with labeling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple non-label-supported claims about FDA actions (counterfeit warnings), online counterfeit/unauthorized products, OTC availability, and pricing/obtainability were included without support from the provided FDA label excerpts.
Suggested Improvement
Limit statements to the exact label-provided content in the prompt (e.g., indication, Schedule IV status, and adverse reactions). Remove or qualify claims about OTC availability, FDA warnings on counterfeits, market availability, and alternative drugs unless the specific label text is provided.